Sage tweaks primary endpoint for zuranolone depression trial, leaving key durability question unanswered - FierceBiotech

Submitted by Anonymous (not verified) on Tue, 11/02/2021 - 17:47

Sage tweaks primary endpoint for zuranolone depression trial, leaving key durability question unanswered  FierceBiotech